Navigation Links
Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
Date:3/31/2009

Joint Venture to be funded by Cadila Pharmaceuticals and Revenues from Sales of Biogenerics; Deal Includes $11 Million Capital Investment in Novavax

ROCKVILLE, Md., March 31 /PRNewswire-FirstCall/ -- Novavax Inc. (Nasdaq: NVAX) announced today it has formed a joint venture with Cadila Pharmaceuticals Ltd. (Ahmedabad, India) to develop, manufacture and market vaccines, pharmaceuticals and diagnostic products in India. The joint venture will develop and commercialize Novavax's seasonal influenza virus-like-particle (VLP)-based vaccine candidate and Cadila's therapeutic vaccine candidates against cancer as well as its adjuvants, biogeneric and biological diagnostic products for the Indian territory. Novavax will also contribute technology to the joint venture for the development of several other VLP vaccine candidates against diseases of public health concern in that region, such as hepatitis E and Dengue fever. Cadila will contribute approximately $8 million over three years to support the joint venture operations. The joint venture will be responsible for clinical testing and registration of products that will be marketed and sold in India by the joint venture, which will be owned 80 percent by Cadila and 20 percent by Novavax once approval of India Foreign Investment Promotion Board is obtained. Novavax will have the right to negotiate license arrangements of certain vaccines developed by the joint venture for commercialization worldwide outside of India while also having rights to negotiate for other vaccines for commercialization in the US and several other territories outside India.

As part of this strategic alliance, pursuant to a stock purchase agreement dated March 31, 2009, a wholly-owned subsidiary of Cadila will purchase 12.5 million shares of Novavax's common stock at the market price of $0.88 per share, f
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Novavax CEO to Present at BIO CEO & Investor Conference
2. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
3. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
4. Novavax CEO to Present at the World Vaccine Congress 2008
5. Novavax Opens Its First U.S. Vaccine Plant
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. Novavax Reports First Quarter 2008 Financial Results
8. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
9. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
10. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
11. Novavax to Join Russell 3000 Index

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)..., PARIS, November 27 /PRNewswire-FirstCall/...l to market Oralair(R) in both adults and children...the first country where,Oralair(R) has been market...lair(R) is now registered in Austria, Belgium, Bul..., Germany, Greece, Hungary, Ireland, Italy,Latvia...
(Date:11/25/2009)... , BOSTON, Nov. 25 Biotech...virus, genomic data from the 1918 pandemic through...rent H1N1 pandemic, today issued its latest bioche...at the lethality of the H1N1 ("Swine Flu") virus h...the virus,s current outbreak in the spring of 2009...
(Date:11/25/2009)... , BEIJING, Nov. 25 /PRNewswire-Asia/...er and provider of vaccines, announced today that ...blish Sinovac (Dalian) Vaccine,Technology Co., Ltd... produce,and commercialize human-use vaccines. Sin...in developing and commercializing world-class vacc...
(Date:11/24/2009)... , HOUSTON, Nov. 24 /PRNewswire-FirstCall/ -...r of electrical and communications systems and ser...al markets, announced today that its commercial bu...attan Torcon JV to install the electrical systems ... facility at the U.S. Army Medical Research Instit...
Breaking Biology Technology:STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 3Biological H1N1 Vaccines: Too Little, Too Late 2Biological H1N1 Vaccines: Too Little, Too Late 3Biological H1N1 Vaccines: Too Little, Too Late 4Biological H1N1 Vaccines: Too Little, Too Late 5Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3Integrated Electrical Services Awarded Contract to Provide Electrical Systems for U.S. Army Medical Research Institute of Infectious Diseases 2
...s, , , NEW YORK, March 10 Intra-Cellular Therapi...e ITI-007 Phase II trial in patients with Sleep Ma...significantly and dose-dependently increased slow ...r sleep onset as measured by polysomnography (PSG)...ry endpoints of the trial. ITI-007 also increased...
...iotech Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX...ults for its Bio-Seal(TM) Lung Biopsy Tract Plug S...s Annual Scientific Meeting in San Diego, CA. The ... in patients undergoing lung biopsy procedures and... benefit in the group receiving BioSeal. , "We are...
...ate Gary Bauer on Monday called Barack Obama,s dec...onic stem cell research "evidence that ideology is...g the beginnings of a tragedy, as lives will be lo..., The president of American Values made the follow...illing to take tax money from struggling Americans...
Other Biology Technology:Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 2Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 3Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 4Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 5Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 6Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia 7Angiotech announces positive results from Bio-Seal(TM) clinical study 2Angiotech announces positive results from Bio-Seal(TM) clinical study 3Angiotech announces positive results from Bio-Seal(TM) clinical study 4Angiotech announces positive results from Bio-Seal(TM) clinical study 5
(Date:11/26/2009)... out in eight European countries has shown that cl...e pandemic could have a significant role in reduci...e open access journal BMC Infectious Diseases co...and weekends/holidays, finding that they were redu...selt and Antwerp University, Belgium, led a team o...
(Date:11/25/2009)...ne produced in the stomach, may be used to boost r...n,s disease, Yale School of Medicine researchers r...e Journal of Neuroscience . , Parkinson,s disea... in an area of the midbrain known as the substanti...ion. Reduced production of dopamine in late-stage...
(Date:11/25/2009)...of a lifetime, the heart pumps some 250 million li... this, the muscle fibers of the heart have to be e... Wolfgang Rottbauer, vice chair of the Department ...(Chairman: Prof. Dr. H. A. Katus), has discovered ... the smallest muscular unit, the sarcomere. In coo...
Breaking Biology News(10 mins):School closure could reduce swine flu transmission by 21 percent 2Hormone ghrelin can boost resistance to Parkinson's disease 2New genetic cause of cardiac failure discovered 2Pumping Up the Volume in the Face to Reduce Signs of Aging 59774 1Pumping Up the Volume in the Face to Reduce Signs of Aging 59774 2Pumping Up the Volume in the Face to Reduce Signs of Aging 59774 3Detroit Area Physical Therapist Pleads Guilty in Medicare Fraud Scheme 59772 1Detroit Area Physical Therapist Pleads Guilty in Medicare Fraud Scheme 59772 2High Blood Pressure Medicines Show Promise For Treating Heart Disease 5576 1High Blood Pressure Medicines Show Promise For Treating Heart Disease 5576 2High Blood Pressure Medicines Show Promise For Treating Heart Disease 5576 3
...or George Paxinos and Dr Yuri Koutcherov of the Sp...es Medical Research Institute have been awarded ~$...ion to prepare a three-dimensional (3D) atlas of t...stopher Reeve met with Institute scientists during...with their work in spinal injuries research. Profe...
...od could be made healthier by adding an extract of.... , The highly-fibrous seaweed extract, alginate,...kes, burgers and other types of food which usually...healthy nutrients, say the team. , Scientists at ...r findings in the academic journal Critical Review...
...g ship hulls with artificial shark skin could help...nisms such as barnacles on ship hulls is a major c...ry. Shark skin offers a structural design that pre...t from the University of Applied Sciences, Bremen,...n of artificial shark skin in a new anti-fouling s...
Other Biology News:3D Atlas Will Help Navigate The Spinal Cord 2Seaweed could make junk food healthier 2
Safety Glasses Dispensers from Terra Universal, Inc.
Dispensing Bins from Terra Universal, Inc.
...cept that it uses a deep-UV deuterium bulb, which ...ith a shutter (controlled via a TTL signal or swit... powerful, stable output from 215-400 nm. In addit...lable, providing a wavelength range of 190-400 nm....
...sis and mitochondrial membrane potential. The mito...n early indication of the initiation of cellular a...ollapse in the electrochemical gradient across the... in the membrane potential (YD). Loss of mitochond...
Biology Products: